IFNG +874T/A polymorphism is not associated with American tegumentary leishmaniasis susceptibility but can influence Leishmania induced IFN-γ production by Matos, Guilherme Inocêncio et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
IFNG +874T/A polymorphism is not associated with American 
tegumentary leishmaniasis susceptibility but can influence 
Leishmania induced IFN-γ production
Guilherme Inocêncio Matos2, Claudia de J Fernandes Covas1, Rita de 
Cássia Bittar1, Adriano Gomes-Silva1, Fabiana Marques3, Viviane C Maniero2, 
Valdir S Amato4, Manoel P Oliveira-Neto5, Marise da Silva Mattos5, 
Claude Pirmez3, Elizabeth P Sampaio2, Milton O Moraes2 and 
Alda Maria Da-Cruz*1
Address: 1Laboratório de Imunoparasitologia, Departamento de Imunologia, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil, 
2Laboratório de Hanseníase, Departamento de Micobacterioses, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil, 3Laboratório de 
Imunopatologia, Departamento de Bioquímica e Biologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil, 4Ambulatório de 
Leishmanioses, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil 
and 5Instituto de Pesquisa Clínica Evandro Chagas (IPEC), FIOCRUZ, Rio de Janeiro, Brazil
Email: Guilherme Inocêncio Matos - gmatos@ioc.fiocruz.br; Claudia de J Fernandes Covas - claudiacovas@wnetrj.com.br; Rita de 
Cássia Bittar - rita_bittar@hotmail.com; Adriano Gomes-Silva - gomesas@ioc.fiocruz.br; Fabiana Marques - fabimaq@yahoo.com.br; 
Viviane C Maniero - vivianemaniero@yahoo.com.br; Valdir S Amato - valdirsa@netpoint.com.br; Manoel P Oliveira-
Neto - onetohec@ipec.fiocruz.br; Marise da Silva Mattos - m.s.mattos@ipec.fiocruz.br; Claude Pirmez - pirmez@ioc.fiocruz.br; 
Elizabeth P Sampaio - esampaio@ioc.fiocruz.br; Milton O Moraes - mmoraes@fiocruz.br; Alda Maria Da-Cruz* - alda@ioc.fiocruz.br
* Corresponding author    
Abstract
Background: Interferon-gamma is a key cytokine in the protective responses against intracellular pathogens. A single
nucleotide polymorphism (SNP) located in the first intron of the human IFN-γ gene can putatively influence the secretion
of cytokine with an impact on infection outcome as demonstrated for tuberculosis and other complex diseases. Our aim
was to investigate the putative association of IFNG+874T/A SNP with American tegumentary leishmaniasis (ATL) and
also the influence of this SNP in the secretion of IFN-γ in vitro.
Methods: Brazilian ATL patients (78 cutaneous, CL, and 58 mucosal leishmaniasis, ML) and 609 healthy volunteers were
evaluated. The genotype of +874 region in the IFN-γ gene was carried out by Amplification Refractory Mutational System
(ARMS-PCR). Leishmania-induced IFN-γ production on peripheral blood mononuclear cell (PBMC) culture supernatants
was assessed by ELISA.
Results: There are no differences between +874T/A SNP frequency in cases and controls or in ML versus CL patients.
Cutaneous leishmaniasis cases exhibiting AA genotype produced lower levels of IFN-γ than TA/TT genotypes. In mucosal
cases, high and low IFN-γ producers were clearly demonstrated but no differences in the cytokine production was
observed among the IFNG +874T or A carriers.
Conclusion: Our results suggest that +874T/A polymorphism was not associated with either susceptibility or severity
to leishmaniasis. Despite this, IFNG +874T/A SNP could be involved in the pathogenesis of leishmaniasis by influencing
the amount of cytokine released by CL patients, although it could not prevent disease development. On the other hand,
it is possible that in ML cases, other potential polymorphic regulatory genes such as TNF-α and IL-10 are also involved
thus interfering with IFN-γ secretion.
Published: 24 April 2007
BMC Infectious Diseases 2007, 7:33 doi:10.1186/1471-2334-7-33
Received: 11 September 2006
Accepted: 24 April 2007
This article is available from: http://www.biomedcentral.com/1471-2334/7/33
© 2007 Matos et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2007, 7:33 http://www.biomedcentral.com/1471-2334/7/33
Page 2 of 6
(page number not for citation purposes)
Background
American tegumentary leishmaniasis (ATL) is a vector
born disease caused in Brazil mainly by Leishmania (Vian-
nia) braziliensis, an intracellular pathogen. This unique
Leishmania species can cause a spectrum of clinical presen-
tation ranging from self-healing or benign cutaneous
lesions (CL) to more severe forms, such as mucosal leish-
maniasis (ML). ML is not as common as CL, affecting
approximately 5% of patients infected almost exclusively
by L. braziliensis [1], indicating that host intrinsic factors
can predispose for severity. The outcome of infection is
profoundly influenced by the balance between effector
and regulatory specific T-cell responses in which a higher
immunoresponsiveness to leishmanial antigens accounts
for worsened prognosis of the disease [2-5].
Susceptibility to infectious diseases is influenced by the
genetic background and it is supposed that efficient acti-
vation of cellular immune response specifically the IFNG/
IL-12/23 axis might play a key role in protection [6]. In
leishmaniasis, cytokines such as interferon-gamma (IFN-
γ) and tumor necrosis factor alpha (TNF-α) have a major
role in controlling intracellular growth of the etiological
pathogen. Suitable amounts of TNF-α and IFN-γ pro-
duced by subclinical or CL patients are proven to be
important in mediating cure, but over expression of both
cytokines generated in consequence of exacerbated
immune response can induce intense pathological dam-
age, as observed in ML [3,4,7-9]. Importantly, clinical cure
of ML is directly related to a decrease in TNF-α levels [8-
10], but not IFN-γ [4]. Despite this, even long-term cured
ML patients still produce higher IFN-γ levels than CL indi-
cating that some individuals maintain their ability to con-
tinuously produce significant amounts of this cytokine
[4]. Interestingly, high and low IFN-γ producers are clearly
seen among cured ML patients [4]. Such data suggest that
genetic factors potentially drive IFN-γ secretion upon
leishmanial stimuli and have the potential to determine
the clinical evolution or even predisposition for more
severe forms of the disease.
A single nucleotide polymorphism (SNP) located in the
first intron of the human IFN-γ gene, at the 5' end adjacent
to a CA repeat region (+874T/A polymorphism) can puta-
tively influence the secretion of IFN-γ [11]. Analysis of the
biological role of this SNP suggested that +874A carriers
are low IFN-γ producers [12]. This finding can explain
why a high frequency of +874A allele has been eventually
associated with susceptibility to tuberculosis in different
population [12-16]. However, this SNP is a still controver-
sial issue regarding risk for acquiring tuberculosis since no
association with susceptibility to this disease was demon-
strated by other authors [17] even when larger and ethni-
cally different population were studied [18].
Susceptibility to other infectious diseases like severe acute
respiratory syndrome (SARS) have also been described
[19] suggesting that variability in IFN-γ production linked
to this SNP is possibly playing a major role in susceptibil-
ity to infectious diseases, especially intracellular patho-
gens.
Previous reports have shown that polymorphism located
in the TNF-α promoter -308A were in a higher frequency
among ML patients [20], but no data is available for the
IFN-γ genotypic analysis in ATL. It is conceivable that
allelic variants in IFN-γ genes may influence the levels of
released protein [11] which in turn could increase the sus-
ceptibility to leishmaniasis or predispose for progression
to mucosal leishmaniasis. Our aim was to investigate
whether +874T/A of IFN-γ gene increase the risk for devel-
oping cutaneous or mucosal leishmaniasis as well as to
determine whether high and low Leishmania-induced IFN-
γ production can be associated with the existence of this
polymorphism.
Methods
Patients
A total of 136 leishmaniasis patients were enrolled in this
study. Seventy-eight CL patients (50 males and 28
females; mean age ± SD = 34 ± 16 years) and 58 ML (39
males and 19 females; mean age ± SD = 58 ± 11 years)
were included. Patients were referred from endemic areas
of L. braziliensis infection in the state of Rio de Janeiro,
Brazil. The diagnostic criteria were based on clinical, par-
asitological and immunological parameters as described
elsewhere [4]. Patients were reexamined one year after the
end of the therapy and were considered clinically cured at
the moment of this study. A total of 609 healthy individ-
uals (288 females and 321 males) from the same geo-
graphic area (Rio de Janeiro, Brazil) were involved in the
study. Written informed consent was obtained from all
individuals according to protocol approved by the Ethical
Committee for Human Research of the Fundação
Oswaldo Cruz, Brazilian Ministry of Health.
Genotyping of +874T/A SNP
Genomic DNA was extracted using the commercial kit
DNAzol (DNAzol Invitrogen Life Technologies, Gaithers-
burg, MD, USA) according to the manufacture's instruc-
tions. The genotyping of the +874 region in the first intron
of the IFN-γ gene was carried out by Amplification Refrac-
tory Mutational System (ARMS-PCR), with a reaction for
amplification for each allele (A or T) as described previ-
ously [11].
Peripheral blood mononuclear cell culture and IFN-γ 
measurement
PBMC from a total of 60 patients (31 ML and 29 CL) was
obtained by Ficoll-Hypaque density centrifugation and
the cells (3 × 106 per well) stimulated in vitro for 5-daysBMC Infectious Diseases 2007, 7:33 http://www.biomedcentral.com/1471-2334/7/33
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with crude extract of L. braziliensis promastigote antigens
(50 μg/well), as described previously [4], when superna-
tants were recovered and measured by ELISA. The mono-
clonal antibodies and recombinant cytokines were
purchased from Pharmingen (San Diego, CA, USA). The
procedures were performed according to the manufac-
ture's instructions. Samples were tested in duplicate and
the concentration was analyzed using the SOFTmax®PRO
4.0 program (Life Sciences Edition, Molecular Devices
Corporation, USA). Results were expressed in picograms
per milliliters (pg/mL). The minimum IFN-γ levels
detected were 62.5 pg/mL.
Statistical analysis
The case-control study was analyzed using Logistic Regres-
sion Model with correction for sex as a covariate, per-
formed in statistical software, The R Foundation for
Statistical Computing, version 2.1.1 [21].
Results obtained from quantitative variables were ana-
lyzed by One-way Analysis of Variance (ANOVA) with
Tukey-Kramer post-test, using GraphPad Prism version
3.00 for Windows (GraphPad Software, San Diego, CA,
USA).
Results
The genotypic and allelic frequencies of healthy controls
as well as the groups of patients divided in the clinical
forms of ATL are shown in Table 1. Both populations were
found under Hardy-Weinberg Equilibrium for this locus.
Analyses using the genotypic and allelic frequencies when
comparing patients and controls demonstrated no associ-
ation with susceptibility or protection to ATL per se (p =
0.59 for genotypes and p = 0.4735 for alleles). In the same
way, no associations with the severe mucosal form were
found when compared to CL cases (p = 0.561). Despite
the lower frequency of TT genotype among ATL in com-
parison to AA or TA patients, no statistical difference was
observed in comparison to controls or among the patient
population. Indeed the low frequency of TT genotype is
comparable to the one already expected in the general
population (control individuals).
The analysis of IFN-γ production upon Leishmania anti-
gens stimulation showed, as expected, that differences in
the IFN-γ secretion between CL and ML were very signifi-
cant (p < 0.001). In order to evaluate the functional influ-
ence of SNP +874 in the production of IFN-γ (mean ± SD)
observed in these clinical forms of ATL, a comparison of
leishmanial induced cytokine levels produced in each
genotype was carried-out (Figure 1). In ML patients, simi-
lar levels of IFN-γ were produced independently of the
IFNG +874 genotype (p = 0.09): AA = 9,504 ± 7,858 pg/
mL (median = 11,740 pg/mL; n = 11), TA = 9,522 ± 8,995
pg/mL (median = 5,582 pg/mL; n = 11) and TT = 2,406 ±
2,883 pg/mL (median = 1,884 pg/mL, n = 5). In addition,
ML patients can be clearly (p < 0.0001) separated into two
groups according to the levels of IFN-γ production: high
(>10.000 pg/ml; 15,700 ± 5,866 pg/ml, n = 12) and low
(<10.000 pg/ml; 2,191 ± 2,192 pg/ml, n = 15). This pro-
file of IFN-γ producers was observed indistinctively
among AA and TA genotypes. On the other hand, CL
patients presented significant differences when IFN-γ pro-
duction was compared among patients from the three
IFNG +874 genotypes (p = 0.01). The detectable IFN-γ val-
ues were lower for +874AA individuals (844 ± 1,099 pg/
mL, median = 244 pg/mL, n = 10); moderate for +874TA
(2,700 ± 1,818 pg/mL, median = 2,556 pg/mL, n = 08)
and high in +874TT (4,162 ± 1,678 pg/mL, n = 2). Pos-test
indicates that significant differences were observed
between +874AA and +874TA (p < 0.05). In 11 CL and 2
ML the IFN-γ values were under the minimum detectable
levels.
Discussion
A great deal of evidence indicates that susceptibility to
leishmaniasis or other infectious diseases can be related to
genetic variability at cytokine loci  [15,20,22,23]. After
exposition to L. braziliensis, a host can acquire infection
without developing the disease, or progress through sev-
eral stages from mild CL to severe ML disease. In L. bra-
ziliensis  infection the downmodulation of a type 1
response predispose for the development of CL [7], while
higher levels of IFN-γ are observed in association with
mucosal disease [3,4].
Our results indicate that IFNG +874 SNP was not associ-
ated with development of leishmaniasis per se or progres-
sion to severe forms. However, a decreased frequency of
the homozygous (TT) genotype was observed in CL and
also in ML patients when compared to controls (Table 1).
An association between reduced +874TT IFN-γ
homozygous frequency and chronicity of the disease was
also observed in Sicilian tuberculosis patients [16]. On the
other hand, this SNP seems to impact on in vitro produc-
tion of IFN-γ in CL, where the T allele was associated with
higher levels of this cytokine. As expected for IFNG +874
polymorphism [11], cured CL cases exhibiting AA geno-
type presented significantly lower amounts of Leishmania-
stimulated IFN-γ levels than TA/TT genotypes. Similar
results were obtained in active tuberculosis patients and
this profile is maintained even months after the clinical
cure, indicating that the intrinsic patients' ability to pro-
duced IFN-γ was not affected [12]. Due to a still controver-
sial role of this SNP in influencing the outcome of
intracellular infections [16,17], it is possible that a larger
or a different population (eg  from other Brazilian
endemic areas) would show a positive relationship with
either severity or susceptibility to leishmaniasis as shown
in tuberculosis patients.BMC Infectious Diseases 2007, 7:33 http://www.biomedcentral.com/1471-2334/7/33
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In ML cases no differences in the IFN-γ production was
observed among the IFNG +874 genotypes. It is possible
that under an exacerbated response, which is observed in
ML even after clinical cure [4], the presence (or absence)
of the T allele does not affect the levels of IFN-γ. No asso-
ciation was observed between the time of cure after ther-
apy and the levels of IFN-γ production. However, we can
not rule out the hypothesis that longer period of illness
may induce, in some patients, a sustained hyperrespon-
siveness to leishmanial antigens due to a chronic parasite
activation [24]. Nevertheless, not only the presence of
IFN-γ per se but also the secretion levels of others cytokines
(like TNF-α and IL-10) constitute key factors in immu-
noregulating the host-parasite relationship [3,5,8,9],
demonstrating that many genomic variations located in
others candidate genes can contribute for phenotypic
expression [25].
Taken together, our results reinforce the idea that IFNG
+874 SNP has a functional role in the regulation of the
gene in response to intracellular pathogens. However, it
can be hypothesized that depending on the immunopath-
ogenic characteristics influencing the clinical status of the
patient (CL or ML) different signaling pathways are acti-
vated inducing distinct transcriptional factors [11,13]
leading, as a consequence, to differential levels of IFN-γ
production under similar stimulation conditions.
Conclusion
Despite of being caused by the same Leishmania species,
CL and ML patients have distinct immunoregulatory
mechanisms induced by this parasite which can explain
the difference on the pathogenesis, the therapeutic
response and maybe the prognosis of the disease. The
complex interactions which occur after parasite infection
predict that the clinical course of the disease could not be
explained by a unique mechanism. Our results demon-
strate that IFNG +874T/A SNP could be involved in the
pathogenesis of leishmaniasis by influencing the amount
of IFN-γ released by CL patients, although it could not pre-
vent disease development. It is possible that in ML cases
other potential polymorphic regulatory genes such as
TNF-α and IL-10 are also involved which in turn can influ-
ence the IFN-γ production.
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Table 1: Distribution of genotypic and allelic frequencies among American tegumentary leishmaniasis (ATL) patients (mucosal and 
cutaneous forms) and healthy controls.
Subjects studied IFN-γ (+874 T/A) genotypes number of cases (%) Allele frequencies (%)
AA TA TT A T
ATL patients 57 (0.42) 62 (0.46) 17 (0.12) 0.59 0.41
Cutaneous 
leishmaniasis
30 (0.38) 38 (0.49) 10 (0.13) 0.63 0.37
Mucosal leishmaniasis 27 (0.47) 24 (0.41) 7 (0.12) 0.67 0.33
Healthy controls 224 (0.37) 273 (0.45) 112 (0.18) 0.59 0.41BMC Infectious Diseases 2007, 7:33 http://www.biomedcentral.com/1471-2334/7/33
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Peripheral blood mononuclear cells – PBMC
Amplification refractory mutational system-Polymerase
Chain Reaction – ARMS-PCR
Standard deviation – SD
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